NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Fortress Biotech, Inc. (FBIO) Stock Analysis

Fortress Biotech, Inc. (FBIO) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

FBIO

$1.94

$0.00 (0.00%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare FBIO with… →

FBIO Key Statistics

As of Oct 21, 2026
Trading
Open
$1.95
Previous Close
$1.94
Day's Range
1.92–1.96
52-Week Range
1.83–4.53
Volume
178.19K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.25
Valuation
Market Cap
$64.70M
P/E Ratio
0.70
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
0.95
EPS (ttm)Profit attributable to each share over the last twelve months.
2.76
Financials (FY)
Revenue (FY)
$63.26M+9.69%
Net Income (FY)
$6.82M
Profit marginThe share of revenue left as profit after all costs and taxes.
163.32%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
33.35M
1-Year Return
−29.96%
Dividend and dates
Avg Volume
440.70K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, FBIO closed at $1.94, −29.96% over 1 year.

Fortress Biotech, Inc. (FBIO) has a market capitalization of $64.70M.

In fiscal 2025, FBIO reported revenue of $63.26M.

FBIO Stock Return by Calendar Year

Fortress Biotech, Inc. (FBIO) 10-year return: what $10,000 became

1 year
$10,000 $7,004
−29.96%
5 years
$10,000 $425
−95.75%
10 years
$10,000 $492
−95.08%

If you had invested $10,000 in Fortress Biotech, Inc. (FBIO) 10 years ago, at the close on October 21, 2016, it would have been worth $492 at the close on October 21, 2026: −95.08% in total, −26.01% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−46.99%
2025+80.30%
2024−32.56%
2023−69.60%
2022−73.60%
2021−21.14%
2020+23.35%
2019+198.84%
2018−78.45%
2017+47.78%
2016 (partial year)−10.00%

As of October 21, 2026.

FBIO Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$63.26M$6.82M10.8%
2024$57.68M−$46.00M−79.8%
2023$84.51M−$60.64M−71.7%
2022$75.74M−$86.58M−114.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$63.26M$42.34M−$70.22M$6.82M10.8%
2024$57.68M$36.80M−$111.24M−$46.00M−79.8%
2023$84.51M$61.62M−$139.20M−$60.64M−71.7%
2022$75.74M$44.97M−$203.56M−$86.58M−114.3%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

FBIO Valuation vs Biotechnology Median

Median of 608 stocks
MetricFBIOBiotechnology medianvs median
P/E0.7016.600.0x the median
P/S ratio0.9513.300.1x the median
Profit margin163.32%−38.31%201.6 pts above

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 7 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Fortress Biotech, Inc. (FBIO) carries a market capitalisation of $64.70M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 78 employees.

The most recent close on file for FBIO is $1.94, dated October 21, 2026. The close was unchanged from the previous session. The 52-week range on file runs from $1.83 to $4.53. The latest close sits 6.01% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $63.26M. Against the prior fiscal year total of $57.68M, that is a change of +9.69%. Net income for the same year was $6.82M. Profit margin runs at 163.32%. That is 201.6 percentage points above the Biotechnology median of −38.31%. Earnings per share on a trailing basis come to 2.76.

Across the 4 fiscal years on file, revenue moves from $75.74M in 2022 to $63.26M in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

The trailing P/E ratio stands at 0.7. That is 0 times the Biotechnology median of 16.6. The price-to-sales ratio is 0.95. On price-to-sales that is 0.1 times the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 1.25. Daily returns over the trailing 10 years annualize to a volatility of 85.58%. Over the trailing twelve months the total return is −29.96%. Measured over 10 years, that is −26.01% a year compounded.

Growth & Income

The record shows no dividend for FBIO.

So far in 2026 the total return is −46.99%. The strongest complete calendar year on file is 2019 at +198.84%; the weakest is 2018 at −78.45%. Of the 9 complete calendar years on file, 4 finished higher.

Peer Comparison

Fortress Biotech, Inc. (FBIO) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Fortress Biotech, Inc. FBIO $64.70M 0.7
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Fortress Biotech, Inc. trades at a P/E of 0.7.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Fortress Biotech, Inc.

Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of lesions of non-nodular moderate to severe acne vulgaris; Zilxi, a minocycline topical foam for the treatment of lesions of rosacea; Exelderm, an antifungal cream for topical use; Targadox, an oral doxycycline drug for the therapy of severe acne; Luxamend, a water-based emulsion for the treatment of superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, first and second-degree burns, and radiation dermatitis; and UNLOXCYT, a death-ligand 1 blocking antibody for the treatment of metastatic cutaneous squamous cell carcinoma. It also develops CUTX-101, a copper histidinate injection, which is in FDA approved stage for the treatment of Menkes disease; IV Tramadol, an intravenous formulation, which is in NDA/BLA filed stage for the treatment of post-operative acute pain; Dotinurad, a urate transporter inhibitor, which is in Phase III for the treatment of gout and chronic kidney diseases; CAEL-101, a light chain fibril-reactive monoclonal antibody, which is in Phase III for the treatment of amyloid light chain amyloidosis; and Triplex, a universal recombinant modified vaccinia ankara viral vector vaccine, which is in Phase II for the treatment of cytomegalovirus, anti-human immunodeficiency virus, non-hodgkin lymphoma, and acute lymphoblastic leukemia. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

Visit website →